These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 11010689)

  • 21. Medical devices: reports of corrections and removals; delay of effective data--FDA. Direct final rule; delay of effective date.
    Fed Regist; 1998 Nov; 63(222):63983. PubMed ID: 10339047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-free number for reporting adverse events on labeling for human drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Oct; 73(209):63886-97. PubMed ID: 19112682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical devices; gastroenterology and urology devices; classification of the electrogastrography system. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Sep; 64(184):51442-4. PubMed ID: 11010709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revision of the requirements for live vaccine processing; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Mar; 73(46):12262-3. PubMed ID: 18464339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical devices; medical device, user facility, distributor, and manufacturer reporting, certification, and registration--FDA. Tentative final rule.
    Fed Regist; 1991 Nov; 56(228):60024-39. PubMed ID: 10115705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Removal of regulations regarding certification of drugs composed wholly or partly of insulin; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(92):26690-3. PubMed ID: 10179340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical devices; exemption from premarket notification and reserved devices; class I. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan; 65(10):2296-323. PubMed ID: 11010655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of communicable diseases; restrictions on African rodents, prairie dogs, and certain other animals. Interim final rule; supplement and partial reopening of comment period.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Feb; 72(34):7825-6. PubMed ID: 17319058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Administrative practices and procedures; internal agency review of decisions--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Sep; 63(184):50757. PubMed ID: 10185804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. General and plastic surgery devices; effective date of requirement for premarket approval of the silicone inflatable breast prosthesis. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.
    Fed Regist; 1999 Aug; 64(160):45155-61. PubMed ID: 10558602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical device reporting: manufacturer reporting, importer reporting, user facility reporting, distributor reporting--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Aug; 63(166):45716-7. PubMed ID: 10182694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical chemistry devices; classification of the biotinidase test system. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Mar; 65(61):16520-1. PubMed ID: 11010644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.